|
OALib Journal期刊
ISSN: 2333-9721
费用：99美元
|
|
|
|
常见肠、肝、肾疾病以及糖尿病状态下相关药物转运体的变化及其应用意义
, PP. 127-132
Keywords: 转运体,肠道疾病,肝脏疾病,肾脏疾病,糖尿病
Abstract:
转运体是位于细胞膜上的功能性膜蛋白。目前研究证明转运体在药物的吸收、分布以及排泄过程中发挥着重要的作用,其中以肠道、肝脏以及肾脏转运体的作用最为明显。疾病状态下转运体的表达和功能会发生改变,影响药物在体内的处置过程,使药物的药代动力学发生明显改变而对疾病的药物治疗产生影响。本文综述了常见肠道疾病、肝脏疾病、肾脏疾病以及糖尿病状态下相关转运体的变化及其对临床药物治疗的影响。
| [1] | gaok,sunj,hezg.significantroleofintestinaltransportersindrugabsorption[j].actapharmsin(药学学报),2006,41:97-102.
|
| [2] | wangw,liuq,wangc,etal.effectsofjbp485ontheexpressionandfunctionofpept1inindomethacin-inducedintestinalinjuryinratsanddamageincaco-2cells[j].peptides,2011,32:946-955.
|
| [3] | liuz,wangc,liuq,etal.uptake,transportandregula-tionofjbp485bypept1invitroandinvivo[j].peptides,2011,32:747-754.
|
| [4] | trdanlusint,mrhara,stiegerb,etal.influenceofhepaticandintestinaleffluxtransportersandtheirgeneticvariantsonthepharmacokineticsandpharmacodynamicsofraloxifeneinosteoporosistreatment[j].translres,2012,160:298-308.
|
| [5] | hardwickrn,fishercd,canetmj,etal.variationsinatp-bindingcassettetransporterregulationduringthepro-gressionofhumannonalcoholicfattyliverdisease[j].drugmetabdispos,2011,39:2395-2402.
|
| [6] | niesat,koepsellh,winters,etal.expressionofor-ganiccationtransportersoct1(slc22a1)andoct3(slc22a3)isaffectedbygeneticfactorsandcholestasisinhumanliver[j].hepatology,2009,50:1227-1240.
|
| [7] | martinez-becerrap,vaqueroj,romeromr,etal.nocorrelationbetweentheexpressionoffxrandgenesinvolvedinmultidrugresistancephenotypeofprimarylivertumors[j].molpharm,2012,9:1693-1704.
|
| [8] | heisem,lautema,knapsteinj,etal.downregulationoforganiccationtransportersoct1(slc22a1)andoct3(slc22a3)inhumanhepatocellularcarcinomaandtheirprognosticsignificance[j].bmccancer,2012,12:109.
|
| [9] | lautema,heisem,grasela,etal.downregulationoforganiccationtransporter1(slc22a1)isassociatedwithtumorprogressionandreducedpatientsurvivalinhumancholangio-cellularcarcinoma[j].intjoncol,2013,42:1297-1304.
|
| [10] | schaeffelere,hellerbrandc,niesat,etal.dnamethylationisassociatedwithdownregulationoftheorganiccationtransporteroct1(slc22a1)inhumanhepatocellularcarcinoma[j].genomemed,2011,3:82.
|
| [11] | jinhe,hongss,choimk,etal.reducedantidiabeticeffectofmetforminanddown-regulationofhepaticoct1inratswithethynylestradiol-inducedcholestasis[j].pharmres,2009,26:549-559.
|
| [12] | naudj,michaudj,beauchemins,etal.effectsofchronicrenalfailureonkidneydrugtransportersandcyto-chromep450inrats[j].drugmetabdispos,2011,39:1363-1369.
|
| [13] | kouidhis,berrhoumar,rouissik,etal.humansubcutaneousadiposetissueglut4mrnaexpressioninobesityandtype2diabetes[j].actadiabetol,2013,50:227-232.
|
| [14] | leejh,yangsh,ohjm,etal.pharmacokineticsofdrugsinratswithdiabetesmellitusinducedbyalloxanorstreptozocin:comparisonwiththoseinpatientswithtypeidiabetesmellitus[j].jpharmpharmacol,2010,62:1-23.
|
| [15] | yus,yuy,liul,etal.increasedplasmaexposuresoffiveprotoberberinealkaloidsfromcoptidisrhizomainstreptozotocin-induceddiabeticrats:isp-gpinvolved?[j].plantamed,2010,76:876-881.
|
| [16] | zhangll,lul,jins,etal.tissue-specificalterationsinexpressionandfunctionofp-glycoproteininstreptozoto-cin-induceddiabeticrats[j].actapharmacolsin,2011,32:956-966.
|
| [17] | nowickimt,aleksuneslm,sawantsp,etal.renalandhepatictransporterexpressionintype2diabeticrats[j].drugmetablett,2008,2:11-17.
|
| [18] | gangopadhyaya,thamotharanm,adibisa.regulationofoligopeptidetransporter(pept-1)inexperimentaldiabetes[j].amjphysiolgastrointestliverphysiol,2002,283:g133-138.
|
| [19] | hindletp,barraudc,boschatl,etal.rosiglitazoneandmetforminhaveoppositeeffectsonintestinalabsorptionofoligopeptidesviatheproton-dependentpept1transporter[j].molpharmacol,2012,81:319-327.
|
| [20] | zolko,frommmf.transporter-mediateddruguptakeandefflux:importantdeterminantsofadversedrugreactions[j].clinpharmacolther,2011,89:798-805.
|
| [21] | eichelbaumm,greinerb,fritzp,etal.theroleofintes-tinalp-glycoproteinintheinteractionofdigoxinandrifampin[j].jclininvestig,2002,110:571.
|
| [22] | shitaray,hiranom,satoh,etal.gemfibrozilanditsglucuronideinhibittheorganicaniontransportingpolypeptide2(oatp2/oatp1b1:slc21a6)-mediatedhepaticuptakeandcyp2c8-mediatedmetabolismofcerivastatin:analysisofthemechanismoftheclinicallyrelevantdrug-druginteractionbetweencerivastatinandgemfibrozil[j].jpharmacolexpther,2004,311:228-236.
|
| [23] | verbeeckrk.pharmacokineticsanddosageadjustmentinpatientswithhepaticdysfunction[j].eurjclinpharmacol,2008,64:1147-1161.
|
| [24] | zhangj,liukx.intestinalabsorptionandrenalexcretionmediatedbytransportersandtherelationshipwithdrug-druginteraction[j].actapharmsin(药学学报),2010,45:1089-1094.
|
| [25] | zengx,bihc,huangm.areviewonregulationofdrugtransportersduringinflammation[j].actapharmsin(药学学报),2011,46:773-779.
|
| [26] | estudantem,moraisjg,soveralg,etal.intestinaldrugtransporters:anoverview[j].advdrugdelivrev,2013,65:1340-1356.
|
| [27] | ingersollsa,ayyadurais,charaniama,etal.theroleandpathophysiologicalrelevanceofmembranetransporterpept1inintestinalinflammationandinflammatoryboweldisease[j].amjphysiolgastrointestliverphysiol,2012,302:g484-492.
|
| [28] | vavrickasr,muschmw,fujiyam,etal.tumornecrosisfactor-alphaandinterferon-gammaincreasepept1expressionandactivityinthehumancoloncarcinomacelllinecaco-2/bbeandinmouseintestine[j].pflugersarch,2006,452:71-80.
|
| [29] | dalmassog,nguyenht,charrier-hisamuddinl,etal.pept1mediatestransportoftheproinflammatorybacterialtripeptidel-ala-γ-d-glu-meso-dapinintestinalepithelialcells[j].amjphysiolgastrointestliverphysiol,2010,299:g687-696.
|
| [30] | buysem,tsocasa,walkerf,etal.pept1-mediatedfmlptransportinducesintestinalinflammationinvivo[j].amjphysiolcellphysiol,2002,283:c1795-1800.
|
| [31] | yamamoto-furushojk,mendivil-rangelej,villeda-ramirezma,etal.geneexpressionofcarnitineorganiccationtransporters1and2(octn)isdownregulatedinpatientswithulcerativecolitis[j].inflammboweldis,2011,17:2205-2206.
|
| [32] | wojtalka,elorantajj,hruzp,etal.changesinmrnaexpressionlevelsofsolutecarriertransportersininflammatoryboweldiseasepatients[j].drugmetabdispos,2009,37:1871-1877.
|
| [33] | yamawakih,miharah,suzukin,etal.roleoftransientreceptorpotentialvanilloid4activationinindomethacin-inducedintestinaldamage[j].amjphysiolgastrointestliverphysiol,2014,307:g33-40.
|
| [34] | wenzelu,kuntzs,diestels,etal.pept1-mediatedce-fiximeuptakeintohumanintestinalepithelialcellsisincreasedbyca2+channelblockers[j].antimicrobagentschemother,2002,46:1375-1380.
|
| [35] | lickteigaj,fishercd,augustinelm,etal.effluxtrans-porterexpressionandacetaminophenmetaboliteexcretionarealteredinrodentmodelsofnonalcoholicfattyliverdisease[j].drugmetabdispos,2007,35:1970-1978.
|
| [36] | liut,guox,mengq,etal.effectofjbp485onobstruc-tivejaundiceisrelatedtoregulationofrenaloat1,oat3andmrp2expressioninanit-treatedrats[j].peptides,2012,36:78-85.
|
| [37] | tanakay,aleksuneslm,cuiyj,etal.anit-inducedintrahepaticcholestasisaltershepatobiliarytransporterexpressionvianrf2-dependentandindependentsignaling[j].toxicolsci,2009,108:247-257.
|
| [38] | sunh,frassettol,andbenetlz.effectsofrenalfailureondrugtransportandmetabolism[j].pharmacolther,2006,109:1-11.
|
| [39] | morrisseykm,stockersl,wittwermb,etal.renaltransportersindrugdevelopment[j].annurevphar-macoltoxicol,2013,53:503-529.
|
| [40] | naudj,nolintd,leblondfa,etal.currentunderstand-ingofdrugdispositioninkidneydisease[j].jclinpharmacol,2012,52:10s-22s.
|
| [41] | naudj,michaudj,boisvertc,etal.down-regulationofintestinaldrugtransportersinchronicrenalfailureinrats[j].jpharmacolexpther,2007,320:978-985.
|
| [42] | naudj,michaudj,leblondfa,etal.effectsofchronicrenalfailureonliverdrugtransporters[j].drugmetabdispos,2008,36:124-128.
|
| [43] | guox,mengq,liuq,etal.jbp485improvesgen-tamicin-inducedacuterenalfailurebyregulatingtheexpressionandfunctionofoat1andoat3inrats[j].toxicolapplpharmacol,2013,271:285-295.
|
| [44] | liut,mengq,wangc,etal.changesinexpressionofrenaloat1,oat3andmrp2incisplatin-inducedacuterenalfailureaftertreatmentofjbp485inrats[j].toxicolapplpharmacol,2012,264:423-430.
|
| [45] | huangs,czechmp.theglut4glucosetransporter[j].cellmetab,2007,5:237-252.
|
| [46] | verbeeckrk,musuambaft.pharmacokineticsanddos-ageadjustmentinpatientswithrenaldysfunction[j].eurjclinpharmacol,2009,65:757-773.
|
Full-Text
|
|
Contact Us
service@oalib.com QQ:3279437679 
WhatsApp +8615387084133
|
|
